BioFluidica Exhibits at ASCO 2023
Chicago, IL, June 3-5, 2023 BioFluidica received a record number of visitors at Booth 27172 at the ASCO 2023 Annual Meeting at the McCormick Center in Chicago. [Read More...]
Assessing Breast Cancer Molecular Subtypes Using Extracellular Vesicles’ (EVs’) mRNA
Hu et al., Anal. Chem. 2023 May 16;95(19) 7665-7675 used LiquidScan to affinity capture EVs from plasma of breast cancer patients. Extracellular vesicles (EVs) carry RNA cargo that [Read More...]
BioFluidica Exhibits at AACR 2023, Orlando, FL
April 14-19, 2023 The BioFluidica booth at the recent American Association for Cancer Research, AACR, Annual Conference experienced much attention as scientists learned the potential of EV-subtype-based [Read More...]
HER2+ Breast Cancer Pilot Study
February 9, 2023 Blood was drawn from 16 breast cancer patients and enriched for Circulating Tumor Cells (CTCs) using LiquidScan. Isolated cells were analyzed for HER2 positivity [Read More...]
BioFluidica Exhibits and Presents at PMWC 2023 in Santa Clara, CA
February 9, 2023 BioFluidica attended the Precision Medicine World Conference (PMWC) 2023 on January 25-27th. Every year PMWC gathers top researchers and medical professionals from all over [Read More...]
Liquid Biopsies Take Center Stage at 2022 ASCO Annual Meeting
By Jamie Reno, June 15, 2022 BioFluidica presented its LiquidScan, a microfluidic chip that searches a blood sample for rare biomarkers such as CTCs (circulating tumor cells), cell-free [Read More...]
BioFluidica turns to blood for accurate, inexpensive cancer tests
San Diego Union Tribune | By Bradley J. Fikes, August 31, 2018 Blood is hard to beat for detecting disease. This liquid tissue circulates throughout the body, picking up [Read More...]